Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma

Oncology Letters

Volumn 11, Issue 1, 2016, Pages 293-298

  He, Jiliang ^a   Zhang, Peng ^a   Li, Qinghu ^a   Zhou, Dongsheng ^a   Liu, Ping ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

HMGB1; Marker; Osteosarcoma; Prognosis; Recurrence; Survival rates

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CHILD; CLINICAL FEATURE; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OSTEOSARCOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

EID: 84948798517     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3907     Document Type: Article

References (47)

1. Broadhead ML, Dass CR and Choong PF: Systemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model. Br J Cancer 105: 1503-1511, 2011.
2. Mirabello L, Troisi RJ and Savage SA: International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 125: 229-234, 2009.
3. Cong Y, Li CJ, Zhao JN, Liu XZ and Shi X: Associations of polymorphisms in the bone morphogenetic protein-2 gene with risk and prognosis of osteosarcoma in a Chinese population. Tumour Biol 36: 2059-2064, 2015.
4. Zhang F, Huang W, Sheng M and Liu T: MiR-451 inhibits cell growth and invasion by targeting CXCL16 and is associated with prognosis of osteosarcoma patients. Tumour Biol 36: 2041-2048, 2015.
5. Briccoli A, Rocca M, Salone M, Guzzardella GA, Balladelli A and Bacci G: High grade osteosarcoma of the extremities metastatic to the lung: Long-term results in 323 patients treated combining surgery and chemotherapy, 1985-2005. Surg Oncol 19: 193-199, 2010.
6. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790, 2002.
7. Ren K, Yao N, Wang G, Tian L, Ma J, Shi X, Zhang L, Zhang J, Zhou X, Zhou G, et al: Vasculogenic mimicry: A new prognostic sign of human osteosarcoma. Hum Pathol 45: 2120-2129, 2014.
8. Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV and Hendrix MJ: Tumor cell vasculogenic mimicry: From controversy to therapeutic promise. Am J Pathol 181: 1115-1125, 2012.
9. Schmidt T and Carmeliet P: Angiogenesis: A target in solid tumors, also in leukemia? Hematology Am Soc Hematol Educ Program 2011: 1-8, 2011.
10. Fukumura D, Duda DG, Munn LL and Jain RK: Tumor microvasculature and microenvironment: Novel insights through intravital imaging in pre-clinical models. Microcirculation 17: 206-225, 2010.
11. Cao Z, Bao M, Miele L, Sarkar FH, Wang Z and Zhou Q: Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: A systemic review and meta-analysis. Eur J Cancer 49: 3914-3923, 2013
12. Cao Z, Shang B, Zhang G, Miele L, Sarkar FH, Wang Z and Zhou Q: Tumor cell-mediated neovascularization and lymphangiogenesis contrive tumor progression and cancer metastasis. Biochim Biophys Acta 1836: 273-286, 2013
13. Liu YR, Sun B, Zhao XL, Gu Q, Liu ZY, Dong XY, Che N and Mo J: Basal caspase-3 activity promotes migration, invasion, and vasculogenic mimicry formation of melanoma cells. Melanoma Res 23: 243-253, 2013.
14. Alexandrova EA and Beltchev BG: Acetylated HMG1 protein interacts specifically with homologous DNA polymerase alpha in vitro. Biochem Biophys Res Commun 154: 918-927, 1988.
15. Bonaldi T, Längst G, Strohner R, Becker PB and Bianchi ME: The DNA chaperone HMGB1 facilitates ACF/CHRAC-dependent nucleosome sliding. EMBO J 21: 6865-6873, 2002.
16. Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195, 2002.
17. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A and Lotze MT: Masquerader: High mobility group box-1 and cancer. Clin Cancer Res 13: 2836-2848, 2007.
18. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A and Tracey KJ: Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 126: 389-392, 1999.
19. Tang D, Kang R, Van Houten B, Zeh HJ, Billiar TR and Lotze MT: High mobility group box 1 (HMGB1) phenotypic role revealed with stress. Mol Med 20: 359-362, 2014.
20. Luo Y, Chihara Y, Fujimoto K, Sasahira T, Kuwada M, Fujiwara R, Fujii K, Ohmori H and Kuniyasu H: High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer 49: 741-751, 2013.
21. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, et al: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8: 487-496, 2007.
22. Lin T, Sammy F, Yang H, Thundivalappil S, Hellman J, Tracey KJ and Warren HS: Identification of hemopexin as an anti-inflammatory factor that inhibits synergy of hemoglobin with HMGB1 in sterile and infectious inflammation. J Immunol 189: 2017-2022, 2012.
23. Zhang G, Chen F, Cao Y, Amos JV, Shah G and See WA: HMGB1 release by urothelial carcinoma cells in response to Bacillus Calmette-Guérin functions as a paracrine factor to potentiate the direct cellular effects of Bacillus Calmette-Guérin. J Urol 190: 1076-1082, 2013.
24. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199, 2009.
25. Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655-663, 1982.
26. Broadhead ML, Clark JC, Myers DE, Dass CR and Choong PF: The molecular pathogenesis of osteosarcoma: A review. Sarcoma 2011: 959248, 2011.
27. Aragon-Ching JB and Maki RG: Treatment of adult soft tissue sarcoma: Old concepts, new insights, and potential for drug discovery. Cancer Invest 30: 300-308, 2012.
28. Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer 115: 1531-1543, 2009.
29. Kong C and Hansen MF: Biomarkers in osteosarcoma. Expert Opin Med Diagn 3: 13-23, 2009.
30. Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, Huvos AG, Healey JH and Gorlick R: Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 11: 2561-2567, 2005.
31. Somers GR, Ho M, Zielenska M, Squire JA and Thorner PS: HER2 amplification and overexpression is not present in pediatric osteosarcoma: A tissue microarray study. Pediatr Dev Pathol 8: 525-532, 2005.
32. Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, Tabata K, Hemmi A, Sugitani M, Nemoto N and Ryu J: Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem Cytochem 39: 95-100, 2006.
33. Shen X, Hong L, Sun H, Shi M and Song Y: The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncol Rep 22: 535-539, 2009.
34. Liu F, Zhang Y, Peng Z, Gao H, Xu L and Chen M: High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transl Med 10: 135, 2012.
35. Chuangui C, Peng T and Zhentao Y: The expression of high mobility group box 1 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Pathol Oncol Res 18: 1021-1027, 2012.
36. Chen J, Xi B, Zhao Y, Yu Y, Zhang J and Wang C: High-mobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer. Gynecol Oncol 126: 109-117, 2012.
37. Liu Y, Xie C, Zhang X, Huang D, Zhou X, Tan P, Qi L, Hu G, Tian Y and Qiu Y: Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer 46: 3007-3015, 2010.
38. Hao Q, Du XQ, Fu X and Tian J: Expression and clinical significance of HMGB1 and RAGE in cervical squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi 30: 292-295, 2008 (In Chinese).
39. Kang HJ, Lee H, Choi HJ, Youn JH, Shin JS, Ahn YH, Yoo JS, Paik YK and Kim H: Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Invest 89: 948-959, 2009.
40. Topalova D, Ugrinova I, Pashev IG and Pasheva EA: HMGB1 protein inhibits DNA replication in vitro: A role of the acetylation and the acidic tail. Int J Biochem Cell Biol 40: 1536-1542, 2008.
41. Schlueter C, Weber H, Meyer B, Rogalla P, Röser K, Hauke S and Bullerdiek J: Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 166: 1259-1263, 2005.
42. Sitohy B, Nagy JA and Dvorak HF: Anti-VEGF/VEGFR therapy for cancer: Reassessing the target. Cancer Res 72: 1909-1914, 2012.
43. Wang W, Jiang H, Zhu H, Zhang H, Gong J, Zhang L and Ding Q: Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma. Oncol Lett 5: 884-888, 2013.
44. Tang D, Kang R, Zeh HJ III and Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta 1799: 131-140, 2010.
45. Xiao J, Ding Y, Huang J, Li Q, Liu Y, Ni W, Zhang Y, Zhu Y, Chen L and Chen B: The association of HMGB1 gene with the prognosis of HCC. PLoS One 9: e89097, 2014.
46. Yonemoto T, Tatezaki S, Ishii T, Satoh T, Kimura H and Iwai N: Prognosis of osteosarcoma with pulmonary metastases at initial presentation is not dismal. Clin Orthop Relat Res 349: 194-199, 1998.
47. Daw NC, Billups CA, Rodriguez-Galindo C, McCarville MB, Rao BN, Cain AM, Jenkins JJ, Neel MD and Meyer WH: Metastatic osteosarcoma. Cancer 106: 403-412, 2006.